In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...